
|Articles|February 1, 2004
STAAR Surgical revamps procedures after FDA warning; product complaints at issue
Monrovia, CA-Officials at STAAR Surgical Co. are scrambling to answer questions raised by a warning letter from the FDA that criticized the company for failing to review product complaints adequately and ensure quality control of its manufacturing materials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Beyond the surface: Tackling complex dry eye cases
3
Redefining glaucoma care: Where innovation meets clinical insight
4
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
5



















































.png)


